Incidence, Risk factors, and Outcomes of Thromboembolism in Patients with Melanoma Receiving Immune Checkpoint Inhibitors, Chemotherapy, or Targeted Therapy: a SEER-Medicare Analysis.
- DOI
- 10.1016/j.jtha.2026.09.005
- Published
- 2026-09-12
- Container
- J Thromb Haemost
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jtha.2026.09.005,
title = {Incidence, Risk factors, and Outcomes of Thromboembolism in Patients with Melanoma Receiving Immune Checkpoint Inhibitors, Chemotherapy, or Targeted Therapy: a SEER-Medicare Analysis.},
author = {Sussman TA and Vu L and Koroukian SM and Khorana AA.},
year = {2026},
journal = {J Thromb Haemost},
doi = {10.1016/j.jtha.2026.09.005},
url = {https://doi.org/10.1016/j.jtha.2026.09.005}
}RIS
TY - JOUR TI - Incidence, Risk factors, and Outcomes of Thromboembolism in Patients with Melanoma Receiving Immune Checkpoint Inhibitors, Chemotherapy, or Targeted Therapy: a SEER-Medicare Analysis. AU - Sussman TA AU - Vu L AU - Koroukian SM AU - Khorana AA. PY - 2026 JO - J Thromb Haemost DO - 10.1016/j.jtha.2026.09.005 UR - https://doi.org/10.1016/j.jtha.2026.09.005 ER -
APA
TA, S., L, V., SM, K., & AA., K. (2026). Incidence, Risk factors, and Outcomes of Thromboembolism in Patients with Melanoma Receiving Immune Checkpoint Inhibitors, Chemotherapy, or Targeted Therapy: a SEER-Medicare Analysis.. J Thromb Haemost. https://doi.org/10.1016/j.jtha.2026.09.005
Source records
- europe-pmc · retrieved 2026-09-25T10:45:08.066Z